Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Nov 9;13:1075966. doi: 10.3389/fphar.2022.1075966

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system

Haoning Guo 1, Bin Wang 2, Shuying Yuan 1, Silin Wu 1, Jing Liu 3,*, Miaoquan He 1,*, Jisheng Wang 1,*
PMCID: PMC9683689  PMID: 36438806

In the original article, there was an error in affiliation 1. Instead of “Division of Psychopharmacology, Department of Pharmacy, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Division of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”. In the published article, there was an error in affiliation 3. Instead of “Department of Pathology, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES